Filing Information

Inventor(s)	Menzo J. E. Havenga · Stefan Kostense ·
Assignee(s)	None listed in document.  View assignee updates
Application Number	US12930661
Filing date	01/12/2011
Publication date	06/02/2011
Predicted expiration date	10/23/2023
U.S. Classifications	506/9  · 435/5  ·
International Classifications	C12Q170  · C40B3004  ·
Kind Code	A1
Foreign Priority	NLPCTNL0200671 - 10/23/2002 ·

Patent Family

Abstract

Described are of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, described are assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.

Independent Claims | See all claims (12)

1. 1.-38. (canceled)
2. 39. A method for determining a titer of neutralizing antibodies directed against adenoviruses in a human- or animal-derived blood sample, the method comprising: obtaining a serum sample of the human or animal; culturing host cells which can be infected with a recombinant adenovirus; admixing the serum sample, the host cell culture and the recombinant adenovirus, wherein the recombinant adenovirus comprises a transgene encoding luciferase; incubating the admixture for about 24 hours; determining the activity of luciferase in the admixture; and comparing the activity of luciferase in the admixture to a serum-free control, thereby determining the titer of neutralizing antibodies in the blood sample; wherein the titer of neutralizing antibodies is determinable with 1000 host cells.
3. 40. (canceled)
4. 42. (canceled)
5. 45.-53. (canceled)
6. 56. A high-throughput method for determining a titer of neutralizing antibodies directed against adenoviruses in a human- or animal-derived blood sample, the method comprising: obtaining a serum sample of said human or animal; culturing host cells which can be infected with a recombinant adenovirus; admixing the serum sample, the host cell culture and recombinant adenovirus, wherein the recombinant adenovirus comprises a transgene encoding luciferase; incubating the admixture for about 24 hours; determining the activity of luciferase in the admixture; and comparing the activity of luciferase in the admixture to a serum-free control, thereby determining the titer of neutralizing antibodies in the serum sample; wherein 1000 host cells are sufficient to determine the titer of neutralizing antibodies.
7. 57. A method for determining the relative titers of neutralizing antibodies directed against adenoviruses of different serotypes in a human- or animal-derived blood sample, the method comprising: obtaining a serum sample of said human or animal; providing cultured host cells which can be infected by recombinant adenovirus of a first serotype and a second serotype; admixing a first portion of the serum sample, a first portion of the cultured host cells and a recombinant adenovirus of the first serotype to form a first admixture, wherein the recombinant adenovirus of the first serotype comprises a transgene encoding luciferase; admixing a second portion of the serum sample, a second portion of the cultured host cells and a recombinant adenovirus of the second serotype to form a second admixture, wherein the recombinant adenovirus of the second serotype comprises a transgene encoding luciferase; incubating the admixtures for about 24 hours; determining the activity of luciferase in both the first and second admixtures; and comparing the luciferase activities in the first and second admixtures to a serum-free control, thereby determining the relative titers of neutralizing antibodies to adenoviruses of the first and second serotypes in the serum sample; wherein 1000 host cells will provide a titer of neutralizing antibodies.